Sickle Cell Disease Trial, Recruiting NCT06139510 Sponsor: Duke University Condition: Sickle Cell Disease
Back to Sickle Cell Disease

Sickle Cell Disease Trial, Recruiting

NCT06139510
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 15 and 40 years old and can give written consent (or a parent/guardian can give consent if you are under 18)
  • You have been diagnosed with sickle cell disease (specifically SS, SC, S beta+ thalassemia, or S beta0 thalassemia)
  • You have had at least one sickle cell-related pain episode in the past 12 months that needed to be treated with strong pain medicine (opioids), either at home or in the hospital
  • If you are already taking regular pain medicines (such as ibuprofen, acetaminophen, or opioids), your dose has stayed the same for at least 4 weeks before joining

Who may not be able to join:

  • You are younger than 15 or older than 40 years old
  • You have difficulty understanding or completing the study steps due to a cognitive or mental health condition
  • You are currently pregnant
  • You have had a stroke that has left you with ongoing physical limitations that would prevent you from taking part in the study
  • You had a severe sickle cell pain crisis within the last 2 weeks that sent you to the emergency room or required a hospital stay
  • You currently have an active infection of any kind
  • You have nerve damage (for example, from diabetes), or bone damage in your joints that is currently being treated for pain — or any other condition that the lead doctor feels would make it unsafe or unfair for you to participate (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Martha Kenney, MD, Duke University

Phone: 9196814877

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Registry
ClinicalTrials.gov
Start date
12 July 2024
Est. completion
1 June 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change in pain pain severity

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov